-Mevalonate pathway inhibition (leukaemia).-Inhibition of protein prenylation via upstream HMG-CoA reductase inhibition.-Suppression of Ras and downstream signalling pathways including Erk enhancement of TMZ efficacy. This evidence concerns the gene HMGCR and leukemia.